UCB

UCB is a seasoned player in the biopharmaceutical industry, having been established in 1928. Headquartered in Belgium, this global company is dedicated to creating innovative solutions for those living with severe central nervous system and immunological conditions. With the slogan "We’re #TeamUCB, a global biopharmaceutical company. 💙 Inspired by patients 🔬 Driven by science," the company emphasizes its patient-focused and science-driven approach.

UCB's mission centers around delivering meaningful solutions that extend beyond traditional medicine, focusing on real value both in clinical outcomes and everyday life enhancements. By leveraging insights from patient and caregiver experiences, UCB aims to address unmet needs through transformative science and technologies.

The company's strong global presence spans nearly 40 countries, promoting a culture of respect, collaboration, and innovation. UCB's most recent financial activity includes a €94.50M Post IPO Equity investment in May 2022, backed by Financière de Tubize SA, showcasing continued investor confidence.